151 related articles for article (PubMed ID: 36471872)
21. A Unique mRNA Vaccine Elicits Protective Efficacy against the SARS-CoV-2 Omicron Variant and SARS-CoV.
Guan X; Verma AK; Wang G; Roy A; Perlman S; Du L
Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932334
[TBL] [Abstract][Full Text] [Related]
22. An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.
Yuan M; Zhu Y; Liu G; Wang Y; Wang G; Zhang G; Ye L; Qian Z; Liu P
One Health Adv; 2023; 1(1):12. PubMed ID: 37521533
[TBL] [Abstract][Full Text] [Related]
23. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
25. Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern.
Schwarze M; Krizsan A; Brakel A; Pohl F; Volke D; Hoffmann R
Front Immunol; 2022; 13():915034. PubMed ID: 35784285
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination.
Grikscheit K; Rabenau HF; Ghodratian Z; Widera M; Wilhelm A; Toptan Grabmair T; Hoehl S; Layer E; Helfritz F; Ciesek S
Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891326
[TBL] [Abstract][Full Text] [Related]
27. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.
Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F
Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131
[TBL] [Abstract][Full Text] [Related]
28. Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants.
Chen R; Zhang X; Yuan Y; Deng X; Wu B; Xi Z; Wang G; Lin Y; Li R; Wang X; Zou F; Liang L; Yan H; Liang C; Li Y; Wu S; Deng J; Zhou M; Zhang X; Li C; Bu X; Peng Y; Ke C; Deng K; He X; Zhang Y; Zhang Z; Pan T; Zhang H
Adv Sci (Weinh); 2022 Apr; 9(11):e2105378. PubMed ID: 35142444
[TBL] [Abstract][Full Text] [Related]
29. Identification of nurse shark V
Buffington J; Duan Z; Kwon HJ; Hong J; Li D; Feng M; Xie H; Ho M
FASEB J; 2023 Jun; 37(6):e22973. PubMed ID: 37191949
[TBL] [Abstract][Full Text] [Related]
30. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
31. Monovalent and trivalent VSV-based COVID-19 vaccines elicit neutralizing antibodies and CD8
Parham KA; Kim GN; Richer CG; Ninkov M; Wu K; Saeedian N; Li Y; Rashu R; Barr SD; Arts EJ; Haeryfar SMM; Kang CY; Troyer RM
iScience; 2023 Apr; 26(4):106292. PubMed ID: 36915805
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
33. Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs.
Wang B; Xu J; Wu S; Zhang Z; Zhao Z; Zhang J; Fu L; Zai X; Wang Y; Zhang G; Chen Z; Chen Y; Sun H; Song X; Zhang J; Zhu L; Hou L; Chen W
Signal Transduct Target Ther; 2022 Jul; 7(1):257. PubMed ID: 35906201
[TBL] [Abstract][Full Text] [Related]
34. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
35. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
[TBL] [Abstract][Full Text] [Related]
36. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.
Wang S; Sun H; Zhang Y; Yuan L; Wang Y; Zhang T; Wang S; Zhang J; Yu H; Xiong H; Tang Z; Liu L; Huang Y; Chen X; Li T; Ying D; Liu C; Chen Z; Yuan Q; Zhang J; Cheng T; Li S; Guan Y; Zheng Q; Zheng Z; Xia N
Cell Rep; 2022 May; 39(8):110862. PubMed ID: 35594869
[TBL] [Abstract][Full Text] [Related]
37. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
[TBL] [Abstract][Full Text] [Related]
38. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
[TBL] [Abstract][Full Text] [Related]
39. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.
Ballesteros-Sanabria L; Pelaez-Prestel HF; Ras-Carmona A; Reche PA
Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625733
[TBL] [Abstract][Full Text] [Related]
40. Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants.
Chen L; Qi X; Liang D; Li G; Peng X; Li X; Ke B; Zheng H; Liu Z; Ke C; Liao G; Liu L; Feng Q
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
